ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PCRX vs TYRA // REVENUE GROWTH (YOY)

Pacira BioSciences Inc. (NASDAQ) VS. Tyra Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: PCRX 4 — TYRA 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PCRX VS. TYRA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PCRX TYRA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 79.40% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 1.70% -35.00% +36.70 PCRX /roic <GO>
EV/EBITDA & P/E Valuation 51.6x — — TIE /valuation <GO>
Free Cash Flow Yield 9.42% -6.45% +15.87 PCRX /fcf-yield <GO>
Operating Margin 2.60% — — TIE /operating-margins <GO>
Net Profit Margin 1.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) ACTIVE 3.60% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.33 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 8/9 2/9 +6.00 PCRX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 83.2 49.0 +34.25 PCRX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.45B $1.48B -$26.3M TYRA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PCRX REV TYRA REV PCRX GROSS % TYRA GROSS % PCRX FCF TYRA FCF
FY 2025 $726.4M $0 79.4% — $136.7M -$95.3M
FY 2024 $701.0M $0 75.7% — $178.8M -$70.4M
FY 2023 $675.0M $0 — — $154.6M -$50.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PCRX // BETA —
TYRA // BETA —